PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED

Ratings Ping An Healthcare and Technology Company Limited

Equities

1833

KYG711391022

Market Closed - Hong Kong S.E. Other stock markets 04:08:15 2024-04-18 am EDT			5-day change	1st Jan Change
10.08 ^HKD	+3.38%		-9.03%	-43.24%

Mar. 19	Ping An Healthcare and Technology Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 19	Ping An Healthcare and Technology Company Limited Announces Management Changes	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's share price in relation to its net book value makes it look relatively cheap.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED	-43.24%	1.39B		B-
CVS HEALTH CORPORATION	-12.12%	86.47B		B-
HCA HEALTHCARE, INC.	+9.72%	82.27B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.85%	29.43B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.25%	16.82B		B
FRESENIUS SE & CO. KGAA	-5.06%	15.89B		A-
QUEST DIAGNOSTICS INCORPORATED	-8.68%	14.1B		A-
EUROFINS SCIENTIFIC SE	+1.87%	12.05B		A-
PURE HEALTH HOLDING	-30.00%	12.01B	-	-
DAVITA INC.	+20.38%	11.19B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes